Details
| Stereochemistry | MIXED |
| Molecular Formula | C28H31N5O |
| Molecular Weight | 453.5786 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=C2C(=CN([C@H]3C[C@H](CN4CCCC4)C3)C2=NC=N1)C5=CC=CC(OCC6=CC=CC=C6)=C5
InChI
InChIKey=LSFLAQVDISHMNB-AFARHQOCSA-N
InChI=1S/C28H31N5O/c29-27-26-25(22-9-6-10-24(15-22)34-18-20-7-2-1-3-8-20)17-33(28(26)31-19-30-27)23-13-21(14-23)16-32-11-4-5-12-32/h1-3,6-10,15,17,19,21,23H,4-5,11-14,16,18H2,(H2,29,30,31)/t21-,23-
| Molecular Formula | C28H31N5O |
| Molecular Weight | 453.5786 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15141010
Curator's Comment: # Novartis Pharma AG
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3217394 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15141010 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The insulin-like growth factor-I receptor kinase inhibitor NVP-ADW742 sensitizes medulloblastoma to the effects of chemotherapy. | 2011-06 |
|
| The insulin-like growth factor-1 receptor kinase inhibitor, NVP-ADW742, suppresses survival and resistance to chemotherapy in acute myeloid leukemia cells. | 2010 |
|
| The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. | 2004-05 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15050914
NVP-ADW742 significantly inhibits the serum-stimulated cell proliferation in a variety of tumor cell lines in dose-dependent manner, with IC50 values of 0.1-0.5 μM for the multiple myeloma (MM) cell lines, and the antitumor effects on MM cells can not be overcome by the co-culture with BMSCs. In addition, NVP-ADW742 is active against MM cell lines.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:31:10 GMT 2025
by
admin
on
Mon Mar 31 23:31:10 GMT 2025
|
| Record UNII |
MXS2N5862L
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID70431367
Created by
admin on Mon Mar 31 23:31:10 GMT 2025 , Edited by admin on Mon Mar 31 23:31:10 GMT 2025
|
PRIMARY | |||
|
9825149
Created by
admin on Mon Mar 31 23:31:10 GMT 2025 , Edited by admin on Mon Mar 31 23:31:10 GMT 2025
|
PRIMARY | |||
|
MXS2N5862L
Created by
admin on Mon Mar 31 23:31:10 GMT 2025 , Edited by admin on Mon Mar 31 23:31:10 GMT 2025
|
PRIMARY | |||
|
475488-23-4
Created by
admin on Mon Mar 31 23:31:10 GMT 2025 , Edited by admin on Mon Mar 31 23:31:10 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |